---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049821"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:44:49.666639+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09

## Summary
- Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.
- GAAP diluted EPS $1.09; non-GAAP diluted EPS $2.65, up from $0.48 a year ago.
- GAAP net income $124.8M vs loss $121.4M in Q3 2024; adjusted net income $303.7M.
- 47 abstracts accepted at ASH 2025; pipeline advances with sonrotoclax (BCL2 inhibitor) and BTK CDAC BGB-16673.
- Free cash flow $354.5M, up 548% from $54.7M in Q3 2024.

## SEC filing metadata
- accession: 0001628280-25-049821
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/0001628280-25-049821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/bgne-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049821
- JSON: https://secwatch.observer/filing/0001628280-25-049821.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.